FDA Panel to Review Novo Nordisk's Victoza 3mg - Analyst Blog


Novo Nordisk ( NVO ) announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled an Advisory Committee meeting on Sep 11, 2014, to discuss the new drug application (NDA) submitted by the company for Victoza (liraglutide 3 mg). The company is looking to get Victoza approved for the treatment of adults suffering from obesity (with or without comorbidities) and overweight adults with comorbidities such as hypertension, dyslipidemia, sleep apnea or type II diabetes.

Although the FDA is not bound to accept the recommendations of its Advisory Committee, it usually does so.

We note that Novo Nordisk had filed the NDA for Victoza for the treatment of obesity in Dec 2014. Victoza is also under regulatory process in the EU for the same indication. It is already approved as an adjunct to diet and exercise for the treatment of type II diabetes.

According to the FDA, more than one-third of the U.S. adult population currently suffers from obesity, a health condition that leads to a number of health issues such as high blood pressure, type II diabetes and high cholesterol.

Some drugs currently approved for the treatment of obesity are Roche 's ( RHHBY ) Xenical, Arena Pharmaceuticals, Inc. 's ( ARNA ) Belviq and VIVUS Inc. 's ( VVUS ) Qsymia.

Novo Nordisk needs to bring new products to market considering that Prandin is facing generic competition.

Orexigen Therapeutics' ( OREX ) NB32 is also under FDA review for the treatment of obesity. A feedback is expected by Jun 10, 2014.

Novo Nordisk carries a Zacks Rank #3 (Hold). Vivus holds a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ARENA PHARMA (ARNA): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

OREXIGEN THERAP (OREX): Free Stock Analysis Report

ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report

VIVUS INC (VVUS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: ARNA , NVO , OREX , RHHBY , VVUS



More from Zacks.com:

Related Videos



Most Active by Volume

  • $15.65 ▼ 1.82%
  • $109.27 ▼ 1.00%
  • $9.49 ▼ 0.84%
  • $102.16 ▼ 1.19%
  • $22.75 ▼ 7.26%
  • $42.61 ▼ 2.05%
  • $24 ▼ 2.08%
  • $16.82 ▲ 1.39%
As of 9/4/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com